综述:卡维地洛及其他β受体阻滞剂在门静脉高压与肝硬化管理中的争议
本文综述了β受体阻滞剂尤其是卡维地洛在肝硬化中应用的证据,检索PubMed相关文献。国际指南推荐高危静脉曲张者用非选择性β受体阻滞剂(NSBB)行一级预防,疗效与内镜下套扎相当;NSBB联合套扎也用于二级预防。无大静脉曲张但临床显著门静脉高压者使用NSBB更具争议,但证据显示NSBB尤其卡维地洛可减少失代偿并改善生存。晚期肝硬化伴难治性腹水者需谨慎,但近期证据提示可安全继续使用,过早停药可能有害。
要点
- 国际指南推荐高危静脉曲张者用NSBB行一级预防,疗效与内镜下套扎相当。
- NSBB联合内镜下套扎已确立用于静脉曲张出血的二级预防。
- 无大静脉曲张但临床显著门静脉高压者使用NSBB仍有争议,但证据显示可减少失代偿并改善生存。
核心结论
- 随着NSBB获益独立于静脉曲张出血的证据增多,即延缓失代偿和改善生存,应考虑是否给所有晚期慢性肝病患者使用卡维地洛。
研究设计与样本
- 综述:对PubMed中相关出版物进行综合文献检索。
主要发现
- 国际指南推荐高危静脉曲张者用NSBB行一级预防,疗效与内镜下套扎相当。
- NSBB联合内镜下套扎已确立用于二级预防。
- 无大静脉曲张但临床显著门静脉高压者使用NSBB更具争议,但证据显示NSBB尤其卡维地洛可减少失代偿并改善生存。
- 晚期肝硬化伴难治性腹水者需谨慎,但近期证据提示NSBB可安全继续使用,过早停药可能有害。
关键数值与推荐
- 国际指南推荐高危静脉曲张者使用NSBB行一级预防,疗效与内镜下套扎相当。
- NSBB联合内镜下套扎用于二级预防。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Advanced chronic liver disease is an increasing cause of premature morbidity and mortality in the UK. Portal hypertension is the primary driver of decompensation, including the development of ascites, hepatic encephalopathy and variceal haemorrhage. Non-selective beta blockers (NSBB) reduce portal pressure and are well established in the prevention of variceal haemorrhage. Carvedilol, a newer NSBB, is more effective at reducing portal pressure due to additional α-adrenergic blockade and has additional anti-oxidant, anti-inflammatory and anti-fibrotic effects. AIM: To summarise the available evidence on the use of beta blockers, specifically carvedilol, in cirrhosis, focussing on when and why to start METHODS: We performed a comprehensive literature search of PubMed for relevant publications. RESULTS: International guidelines advise the use of NSBB in primary prophylaxis against variceal haemorrhage in those with high-risk varices, with substantial evidence of efficacy comparable with endoscopic band ligation (EBL). NSBB are also well established in secondary prophylaxis, in combination with EBL. More controversial is their use in patients without large varices, but with clinically significant portal hypertension. However, there is gathering evidence that NSBB, particularly carvedilol, reduce the risk of decompensation and improve survival. While caution is advised in patients with advanced cirrhosis and refractory ascites, recent evidence suggests that NSBB can continue to be used safely, and that premature discontinuation may be detrimental. CONCLUSIONS: With increasing evidence of benefit independent of variceal bleeding, namely retardation of decompensation and improvement in survival, it is time to consider whether carvedilol should be offered to all patients with advanced chronic liver disease.
引用
- Gillespie SL, Hanrahan TP, Rockey DC, et al. Review article: controversies surrounding the use of carvedilol and other beta blockers in the management of portal hypertension and cirrhosis. Aliment Pharmacol Ther. 2023. PMID: 36691947. doi:10.1111/apt.17380
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。